Acute phase of depression treatment - current research and its perspectives on Jessenius Faculty of Medicine

[1] Alonso J, Angermeyer MC, Bernert S et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. ActaPsychiatrSc and Suppl. 2004;420:21-27.Search in Google Scholar

[2] Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment. 2014;10:1297-1307.10.2147/NDT.S41387410697125075188Search in Google Scholar

[3] Baldwin DS, Serenko M, Palo W, Lophaven S, Matz J. The safety and tolerability of vortioxetine (Lu AA21004) in the treatment of adults with major depressive disorder (MDD): a pooled analysis. Int J Psychiatry ClinPract. 2013;17(2 suppl):16-17.Search in Google Scholar

[4] Farsky I, Smetanka A, Dubinska S. Spirituality of patients with selected psychiatric disorders. Osetrovatelstvi a PorodniAsistence. 2012;3(3):433-441.Search in Google Scholar

[5] Haggstrom L, Nielsen RZ, Poulsen L, Danchenko N. A randomised, double blind, active controlled study of vortioxetine (10-20 mg/ day) versus agomelatine (25-50 mg/day) in adults with Major Depressive Disorder with inadequate response to antidepressant treatment. Poster presented at: 26th Congress of the European College of Neuropsychopharmacology (ECNP); October 5-9, 2013; Barcelona, Spain.Search in Google Scholar

[6] Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. IntClinPsychopharmacol. 2012;27(4):215-223.10.1097/YIC.0b013e328354245722572889Search in Google Scholar

[7] Kulhan T, Nosalova G, Ondrejka I. Aktualnealternativya trendy vofarmakoterapiianxioznejdepresie a jejneurobiologickeaspekty. Pokrokyvofarmakologiiv Slovenskejrepublike. 2014;9:118-123.Search in Google Scholar

[8] Mork A, Pehrson A, Brennum LT et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp. Ther. 2012;340(3):666-675. Search in Google Scholar

[9] Ondrejka I, Drimalova M, Frank V. Quality of life in depressed patients. ActaMedicaMartiniana. 2001;1(1):29-34.Search in Google Scholar

[10] Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacology & Therapeutics. 2015;145:43-57.10.1016/j.pharmthera.2014.07.00125016186Search in Google Scholar

[11] Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J ClinPsychopharmacol. 2009;29(3):259-266.10.1097/JCP.0b013e3181a5233f19440080Search in Google Scholar

[12] Tonhajzerova I, Ondrejka I, Chladekova Let al. Heart rate time irreversibility is impaired in adolescent major depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2012;39(1):212-217. 10.1016/j.pnpbp.2012.06.02322771778Search in Google Scholar